Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $47 | $79 | $47 | $73 |
| % Growth | -40.1% | 67.8% | -35.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $47 | $79 | $47 | $73 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $240 | $189 | $164 | $137 |
| G&A Expenses | $64 | $55 | $44 | $36 |
| SG&A Expenses | $64 | $55 | $44 | $36 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $0 | $0 | $0 |
| Operating Expenses | $309 | $244 | $208 | $173 |
| Operating Income | -$262 | -$166 | -$161 | -$101 |
| % Margin | -555.8% | -210.6% | -344.4% | -138% |
| Other Income/Exp. Net | $38 | $19 | $6 | $0 |
| Pre-Tax Income | -$224 | -$147 | -$155 | -$100 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$224 | -$147 | -$155 | -$100 |
| % Margin | -475.6% | -187% | -330.6% | -137.6% |
| EPS | -2.98 | -2.52 | -2.87 | -2.09 |
| % Growth | -18.3% | 12.2% | -37.3% | – |
| EPS Diluted | -2.98 | -2.52 | -2.87 | -2.09 |
| Weighted Avg Shares Out | 75 | 58 | 54 | 48 |
| Weighted Avg Shares Out Dil | 75 | 58 | 54 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38 | $19 | $7 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7 | $4 | $3 | $2 |
| EBITDA | -$216 | -$143 | -$152 | -$98 |
| % Margin | -459.4% | -182.2% | -323.9% | -134.1% |